Our research and development team leverages its expertise across a variety of scientific disciplines to focus on identifying drug compounds for reformulation to achieve:
Our development pipeline is highlighted by two product candidates in Phase III clinical trials, arbaclofen ER, and RVL-1201, as well as multiple ANDAs pending regulatory approval and other products in various stages of development. Several of our pipeline products incorporate our proprietary Osmodex® drug delivery system.
Arbaclofen ER is an extended release formulation of arbaclofen, the R isomer of baclofen, that leverages our proprietary Osmodex® drug delivery system and is being studied for the treatment of spasticity resulting from multiple sclerosis.
In 2017, we initiated our second Phase III clinical trial to evaluate the efficacy of arbaclofen ER. We anticipate completing enrollment of the 510 patient trial by the end of 2018. We are also concurrently conducting a long term safety trial for arbaclofen ER.
RVL-1201 is an oxymetazoline ophthalmic solution being studied for the treatment of acquired blepharoptosis, defined as the drooping of the upper eyelid that usually occurs from a partial or complete dysfunction of the muscles that elevate the upper eyelid.
Health care providers currently have limited options available to treat acquired blepharoptosis and, in the United States, the only approved treatment is blepharoplasty, a complex eye surgery. By contrast, RVL-1201, an eye drop administered once daily, is intended to be a simple non-invasive therapy. The drug is intended to activate the Mueller muscle at the back of the eye thereby lifting the upper eyelid 1 to 2 millimeters.
The mission of Osmotica's Grants and Contributions Office is to partner with the healthcare community to improve patient outcomes in areas of mutual interest through support of educational grants and investigator initiated studies (IIS).
A strong preference will be given to educational grants and IIS applications that address areas of strategic focus for the company in the fields of neurology and ophthalmology.
We seek to selectively acquire or in-license approved products and late-stage product candidates that complement our existing product portfolio, pipeline, technology or commercial infrastructure.
If you have an opportunity that you believe would be of interest to Osmotica, please contact our Business Development team at BD@osmotica.com.